Previous whole exome and whole genome sequencing (WES/WGS) studies identified genome-wide significant associations for late-onset Alzheimer's disease (AD) with rare variants but highlighted the need for larger samples.
Objective
Identify associations of rare coding variants with AD risk in a large-scale, multi-ancestry exome-wide.
Methods
We combined non-overlapping portions of the Alzheimer's Disease Sequencing Project (ADSP) WES (n = 18 717) and WGS (n = 35 014) datasets obtaining a sample (n = 34 202) including participants ages ≥ 60 from four genomic similarity clusters consistent with European ancestry (EA, 9 744 AD cases and 9 095 controls), African American (AA, 1 944 AD cases and 4 215 controls), Caribbean Hispanic (CH 2 344 AD cases and 3 465 controls), and Native American Hispanic (NAH 743 AD cases and 2 652 AD controls) populations. Association of AD with 253,421 bi-allelic variants with minor allele count ≥ 20 in the total sample and each population group was evaluated using GENESIS. Gene-based tests comprising predicted moderate and high-impact variants were performed using SAIGE.
Results
Novel study-wide significant associations (p < 1.97 × 10−7) were identified with variants enriched among the Amish in BTBD8 (rs927193859, p = 1.58 x10−10), LINGO1 (rs150289554, p = 8.60 × 10−8), and KCNG2 (rs140218057, p = 1.77 × 10−7) in the total sample. Population-specific analyses confirmed significant associations with APOE in all groups and detected an association in CH individuals with the PSEN1 missense mutation G206A (p = 3.07 × 10−7), a variant that was previously linked to early-onset AD in Hispanics. Gene-based tests highlighted significant associations with LINGO1 (p = 2.75 × 10−8), DYNLT4 (p = 2.80 × 10−7), and ADCY4 (p = 7.43 × 10−7).
Conclusions
We identified rare variants in novel genes which provide new insights into AD pathogenesis.
MedwayCWAbdul-HaySMimsT, et al.Apoe variant p. V236E is associated with markedly reduced risk of Alzheimer’s disease. Mol Neurodegener2014; 9: 1–5.
3.
BellenguezCKüçükaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet2022; 54: 412–436.
4.
GuerreiroRWojtasABrasJ, et al.TREM2 Variants in Alzheimer's disease. N Engl J Med2013; 368: 117–127.
5.
JonssonTStefanssonHSteinbergS, et al.Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med2013; 368: 107–116.
6.
SimsRVan Der LeeSJNajAC, et al.Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet2017; 49: 1373–1384.
7.
SteinbergSStefanssonHJonssonT, et al.Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet2015; 47: 445–447.
8.
SassiCNallsMARidgePG, et al.ABCA7 P.G215S as potential protective factor for Alzheimer's disease. Neurobiol Aging2016; 46: 235.e1.
9.
VardarajanBNGhaniMKahnA, et al.Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann Neurol2015; 78: 487–498.
10.
ZhangXZhuCBeechamG, et al.A rare missense variant of CASP7 is associated with familial late-onset Alzheimer's disease. Alzheimers Dement2019; 15: 441–452.
11.
LogueMWSchuMVardarajanBN, et al.Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement2014; 10: 609–618.
12.
VardarajanBNZhangYLeeJH, et al.Coding mutations in SORL1 and Alzheimer disease. Ann Neurol2015; 77: 215–227.
13.
HolstegeHHulsmanMCharbonnierC, et al.Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease. Nat Genet2022; 54: 1786–1794.
14.
AnderssonCHHanssonOMinthonL, et al.A genetic variant of the sortilin 1 gene is associated with reduced risk of Alzheimer’s disease. J Alzheimers Dis2016; 53: 1353–1363.
15.
JonssonTAtwalJKSteinbergS, et al.A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature2012; 488: 96–99.
16.
WangLSNajACGrahamRR, et al.Rarity of the Alzheimer disease–protective APP A673T variant in the United States. JAMA Neurol2015; 72: 209–216.
17.
BisJCJianXKunkleBW, et al.Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry2020; 25: 1859–1875.
18.
Greenfest-AllenEValladaresOKuksaPP, et al.NIAGADS Alzheimer's GenomicsDB: a resource for exploring Alzheimer's disease genetic and genomic knowledge. Alzheimers Dement2024; 20: 1123–1136.
19.
NajACLinHVardarajanBN, et al.Quality control and integration of genotypes from two calling pipelines for whole genome sequence data in the Alzheimer’s Disease Sequencing Project. Genomics2019; 111: 808–818.
20.
LeeWPChoiSHSheaMG, et al.Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimers Dement2024; 20: 8470–8483.
21.
LeungYYNajACChouYF, et al.Human whole-exome genotype data for Alzheimer’s disease. Nat Commun2024; 15: 684.
22.
LeungYYValladaresOChouYF, et al.VCPA: genomic variant calling pipeline and data management tool for Alzheimer’s Disease Sequencing Project. Bioinformatics2019; 35: 1768–1770.
23.
DanecekPBonfieldJKLiddleJ, et al.Twelve years of SAMtools and BCFtools. Gigascience2021; 10: giab008.
24.
PurcellSNealeBTodd-BrownK, et al.PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet2007; 81: 559–575.
25.
GogartenSMSoferTChenH, et al.Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics2019; 35: 5346–5348.
26.
ZhouWSoferTChenH, et al.Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet2018; 50: 1335–1341.
27.
ManichaikulAMychaleckyjJCRichSS, et al.Robust relationship inference in genome-wide association studies. Bioinformatics2010; 26: 2867–2873.
28.
JinHChienSMeijerE, et al.Learning from clinical consensus diagnosis in India to facilitate automatic classification of dementia: machine learning study. JMIR Ment Health2021; 8: e27113.
29.
ZhouWZhaoZNielsenJB, et al.Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. Nat Genet2020; 52: 634–639.
30.
ZhouWBiWZhaoZ, et al.SAIGE-GENE+ improves the efficiency and accuracy of set-based rare variant association tests. Nat Genet2022; 54: 1466–1469.
31.
CingolaniPPlattsAWangLL, et al.A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin)2012; 6: 80–92.
32.
McLarenWGilLHuntSE, et al.The ensembl variant effect predictor. Gen Biol2016; 17: 1–4.
33.
GreenwoodAKGockleyJDailyK, et al.Agora: an open platform for exploration of Alzheimer’s disease evidence: genetics/omics and systems biology. Alzheimers Dement2020; 16: e046129.
34.
De JagerPLMaYMcCabeC, et al.A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research. Sci Data2018; 5: 180142.
35.
WangMBeckmannNDRoussosP, et al.The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Sci Data2018; 5: 180185.
36.
AllenMCarrasquilloMMFunkC, et al.Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases. Sci Data2016; 3: 160089.
37.
RavenscroftTAPottierCMurrayME, et al.The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer’s disease in Hispanics in Florida. Am J Neurodegener Dis2016; 5: 94.
38.
WangYSarnowskiCLinH, et al.Key variants via the Alzheimer’s Disease Sequencing Project whole genome sequence data. Alzheimers Dement2024; 20: 3290–3304.
39.
LeeSHeckerJHahnG, et al.On the effect heterogeneity of established disease susceptibility loci for Alzheimer's disease across different genetic ancestries. Alzheimers Dement2024; 20: 3397–3405.
40.
ChenZBoehnkeMFuchsbergerC. Combining sequence data from multiple studies: impact of analysis strategies on rare variant calling and association results. Genet Epidemiol2020; 44: 41–51.
41.
BhérerCEveleighRTrajanoskaK, et al.A cost-effective sequencing method for genetic studies combining high-depth whole exome and low-depth whole genome. NPJ Genom Med2024; 9: 8.
42.
SchubachMMaassTNazaretyanL, et al.CADD V1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions. Nucleic Acids Res2023; 52: D1143–D1154.
43.
AthanESWilliamsonJCiappaA, et al.A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA2001; 286: 2257–2263.
44.
LeeJHKahnAChengR, et al.Disease-related mutations among Caribbean hispanics with familial dementia. Mol Genet Genom Med2014; 2: 430–437.
45.
AndrewsJLFernandez-EnrightF. A decade from discovery to therapy: lingo-1, the dark horse in neurological and psychiatric disorders. Neurosci Biobehav Rev2015; 56: 97–114.
46.
McDonaldCBandtlowCReindlM. Targeting the Nogo receptor complex in diseases of the central nervous system. Curr Med Chem2011; 18: 234–244.
47.
DudemSLargeRJKulkarniS, et al.LINGO1 Is a regulatory subunit of large conductance, Ca2+-activated potassium channels. Proc Natl Acad Sci U S A2020; 117: 2194–2200.
48.
KalafatakisIPapagianniFTheodorakisK, et al.Nogo-a and LINGO-1: two important targets for remyelination and regeneration. Int J Mol Sci2023; 24: 4479.
49.
Fernandez-EnrightFAndrewsJL. Lingo-1: a novel target in therapy for Alzheimer’s disease?Neural Regen Res2016; 11: 88–89.
50.
BaiYMarkhamKChenF, et al.The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics2008; 7: 15–34.
51.
de LaatRMeabonJSWileyJC, et al.LINGO-1 promotes lysosomal degradation of amyloid-β protein precursor. Pathobiol Aging Age Relat Dis2015; 5: 25796.
52.
MathysHDavila-VelderrainJPengZ, et al.Single-cell transcriptomic analysis of Alzheimer’s disease. Nature2019; 570: 332–337.
53.
GrubmanAChewGOuyangJF, et al.A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat Neurosci2019; 22: 2087–2097.
54.
XieYHJiangLZhangY, et al.Antagonizing LINGO-1 reduces activated microglia and alleviates dendritic spine loss in the hippocampus of APP/PS1 transgenic mice. Neurosci Lett2024; 820: 137612.
55.
ZhouYNJiangLZhangY, et al.Anti-LINGO-1 antibody protects neurons and synapses in the medial prefrontal cortex of APP/PS1 transgenic mice. Neurosci Res2023; 193: 28–40.
56.
YangHJiangLZhangY, et al.Anti-LINGO-1 antibody treatment alleviates cognitive deficits and promotes maturation of oligodendrocytes in the hippocampus of APP/PS1 mice. J Comp Neurol2022; 530: 1606–1621.
57.
HeQJiangLZhangY, et al.Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice. Neurobiol Dis2021; 156: 105406.
58.
WuDTangXGuLH, et al.LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice. CNS Neurosci Ther2018; 24: 381–393.
59.
XuJHeTWangL, et al.Molecular cloning and characterization of a novel human BTBD8 gene containing double BTB/POZ domains. Int J Mol Med2004; 13: 193–197.
60.
CHARGE Consortium Hematology Working Group. Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. Nat Genet2016; 48: 867–876.
61.
YangXHeZDongQ, et al.Btbd8 deficiency reduces susceptibility to colitis by enhancing intestinal barrier function and suppressing inflammation. Front Immunol2024; 15: 1382661.
62.
PicciniACastroflorioEValenteP, et al.APache is an AP2-interacting protein involved in synaptic vesicle trafficking and neuronal development. Cell Rep2017; 21: 3596–3611.
63.
BenesFM. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology2010; 35: 239–257.
64.
DevorAAndreassenOAWangY, et al.Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia. Mol Psychiatry2017; 22: 792–801.
65.
LagoSGBahnS. The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. NPJ Genom Med2022; 7: 25.
66.
GelernterJKranzlerHRShervaR, et al.Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry2014; 76: 66–74.
67.
LiXT. Alzheimer’s disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels. Metab Brain Dis2022; 37: 581–587.
68.
Alliance of Genome Resources Consortium. Updates to the Alliance of Genome Resources central infrastructure. Genetics2024; 227: iyae049.
69.
BakerLPCastroflorioEValenteP, et al.Regulation and immunohistochemical localization of βγ-stimulated adenylyl cyclases in mouse hippocampus. J Neurosci1999; 19: 180–192.
70.
WongSTTrinhKHackerB, et al.Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice. Neuron2000; 27: 487–497.
71.
AndrewsSJFulton-HowardBGoateA. Protective variants in Alzheimer’s disease. Curr Genet Med Rep2019; 7: 1–2.
72.
SchwartzMLWilliamsMSMurrayMF. Adding protective genetic variants to clinical reporting of genomic screening results: restoring balance. JAMA2017; 317: 1527–1528.
73.
HarperARNayeeSTopolEJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet2015; 16: 689–701.
74.
De DeynLSleegersK. The impact of rare genetic variants on Alzheimer disease. Nat Rev Neurol2025; 21: 127–139.
75.
PoplinRChangPCAlexanderD, et al.A universal SNP and small-indel variant caller using deep neural networks. Nat Biotechnol2018; 36: 983–987.
76.
MillerNAFarrowEGGibsonM, et al.A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Med2015; 7: 100.
77.
BetschartROThiéryAAguilera-GarciaD, et al.Comparison of calling pipelines for whole genome sequencing: an empirical study demonstrating the importance of mapping and alignment. Sci Rep2022; 12: 21502.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
